Biotech M&A is ripping along now as IPOs surge and venture cash flows. Who's the next big target?
Over the course of the first three days of this week we’ve been treated to two biotech buyouts totaling $9.6 billion — by itself more than …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
